We are live on ! Find out more
DGM

Darwin Global Management Portfolio holdings

AUM $3.77B
1-Year Est. Return 307.72%
This Fund
S&P 500
This Quarter Est. Return
+57.45%
1 Year Est. Return
+307.72%
3 Year Est. Return
+2,873.14%
5 Year Est. Return
+48,315.58%
10 Year Est. Return
–
AUM
$358M
AUM Growth
–
Cap. Flow
+$300M
Cap. Flow %
83.69%
Top 10 Hldgs %
99.7%
Holding
12
New
12
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$110M
2
FATE icon
Fate Therapeutics
FATE
+$59.2M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$56.4M
4
BBIO icon
BridgeBio Pharma
BBIO
+$32M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$17M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XLRN
1
DELISTED
Acceleron Pharma
XLRN
$120M 33.5%
+938,490
New +$110M
FATE icon
2
Fate Therapeutics
FATE
$318M
$86.6M 24.18%
+952,847
New +$59.2M
MRTX
3
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$57.3M 15.99%
+260,876
New +$56.4M
BBIO icon
4
BridgeBio Pharma
BBIO
$15.7B
$47.1M 13.15%
+662,958
New +$32M
SRPT icon
5
Sarepta Therapeutics
SRPT
$1.82B
$19.6M 5.47%
+114,900
New +$17M
IMVT icon
6
Immunovant
IMVT
$8B
$9.2M 2.57%
+199,269
New +$9.21M
CCCC icon
7
C4 Therapeutics
CCCC
$396M
$7.57M 2.11%
+228,595
New +$6.63M
GBIO
8
DELISTED
Generation Bio
GBIO
$5.59M 1.56%
+19,719
New +$6.33M
ARVN icon
9
Arvinas
ARVN
$518M
$2.99M 0.83%
+35,200
New +$1.21M
INBX
10
DELISTED
Inhibrx, Inc. Common Stock
INBX
$1.21M 0.34%
+36,534
New +$972K
FULC icon
11
Fulcrum Therapeutics
FULC
$233M
$718K 0.2%
+61,313
New +$693K
STOK icon
12
Stoke Therapeutics
STOK
$1.81B
$372K 0.1%
+6,000
New +$275K

Similar funds

VVP
Vulcan Value Partners Birmingham, Alabama $3.77B AUM 9.63% 1-Year Est. Return
ABC
Associated Banc-Corp Green Bay, Wisconsin $3.78B AUM 21.74% 1-Year Est. Return
SCA
Snowden Capital Advisors New York $3.76B AUM 23.4% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
VA
VestGen Advisors Inverness, Illinois $3.76B AUM 26.04% 1-Year Est. Return
GCC
Guardian Capital (Canada) Toronto, Ontario, Canada $3.78B AUM 33.04% 1-Year Est. Return
SB
SIG Brokerage New York $3.79B AUM 44.46% 1-Year Est. Return

Darwin Global Management's Q4 2020 Portfolio in Review

Q4 2020 is the first quarter with a 13F filing on record for Darwin Global Management, which disclosed 12 positions worth $358M. Its ten largest holdings account for 100% of the portfolio.

Its largest position is Acceleron Pharma: 938,490 shares worth $120M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets.

  • Darwin Global Management's largest Q4 2020 buy was Acceleron Pharma: 938,490 shares worth $120M.
  • Darwin Global Management's ten largest holdings make up 100% of its $358M portfolio in Q4 2020.
  • Darwin Global Management disclosed 12 positions in Q4 2020, its first 13F filing on record.

Based on Darwin Global Management's 13F filing for Q4 2020, filed 16 Feb 2021.